As of 4:00pm ET
| -0.02 / -0.03%|
The 13 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 84.00, with a high estimate of 139.00 and a low estimate of 74.00. The median estimate represents a +16.21% increase from the last price of 72.28.
The current consensus among 14 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.